Cargando…
Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is a cancer with a meager prognosis due to its chemotherapy resistance. A new treatment method may be magnetic fluid hyperthermia (MFH). Magnetoliposomes (ML), consisting of superparamagnetic iron oxide nanoparticles (SPION) stabilized with a pho...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079353/ https://www.ncbi.nlm.nih.gov/pubmed/33935496 http://dx.doi.org/10.2147/IJN.S288379 |
_version_ | 1783685210259324928 |
---|---|
author | Palzer, Julian Mues, Benedikt Goerg, Richard Aberle, Merel Rensen, Sander S Olde Damink, Steven W M Vaes, Rianne D W Cramer, Thorsten Schmitz-Rode, Thomas Neumann, Ulf P Slabu, Ioana Roeth, Anjali A |
author_facet | Palzer, Julian Mues, Benedikt Goerg, Richard Aberle, Merel Rensen, Sander S Olde Damink, Steven W M Vaes, Rianne D W Cramer, Thorsten Schmitz-Rode, Thomas Neumann, Ulf P Slabu, Ioana Roeth, Anjali A |
author_sort | Palzer, Julian |
collection | PubMed |
description | INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is a cancer with a meager prognosis due to its chemotherapy resistance. A new treatment method may be magnetic fluid hyperthermia (MFH). Magnetoliposomes (ML), consisting of superparamagnetic iron oxide nanoparticles (SPION) stabilized with a phospholipid-bilayer, are exposed to an alternating magnetic field (AMF) to generate heat. To optimize this therapy, we investigated the effects of MFH on human PDAC cell lines and 3D organoid cultures. MATERIAL AND METHODS: ML cytotoxicity was tested on Mia PaCa-2 and PANC-1 cells and on PDAC 3D organoid cultures, generated from resected tissue of patients. The MFH was achieved by AMF application with an amplitude of 40–47 kA/m and a frequency of 270 kHz. The MFH effect on the cell viability of the cell lines and the organoid cultures was investigated at two different time points. Clonogenic assays evaluated the impairment of colony formation. Altering ML set-ups addressed differences arising from intra- vs extracellular ML locations. RESULTS: Mia PaCa-2 and PANC-1 cells showed no cytotoxic effects at ML concentrations up to 300 µg(Fe)/mL and 225 µg(Fe)/mL, respectively. ML at a concentration of 225 µg(Fe)/mL were also non-toxic for PDAC organoid cultures. MFH treatment using exclusively extracellular ML presented the highest impact on cell viability. Clonogenic assays demonstrated remarkable impairment as long-term outcome in MFH-treated PDAC cell lines. Additionally, we successfully treated PDAC organoids with extracellular ML-derived MFH, resulting in notably reduced cell viabilities 2h and 24 h post treatment. Still, PDAC organoids seem to partly recover from MFH after 24 h as opposed to conventional 2D-cultures. CONCLUSION: Treatment with MFH strongly diminished pancreatic cancer cell viability in vitro, making it a promising treatment strategy. As organoids resemble the more advanced in vivo conditions better than conventional 2D cell lines, our organoid model holds great potential for further investigations. |
format | Online Article Text |
id | pubmed-8079353 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-80793532021-04-29 Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids Palzer, Julian Mues, Benedikt Goerg, Richard Aberle, Merel Rensen, Sander S Olde Damink, Steven W M Vaes, Rianne D W Cramer, Thorsten Schmitz-Rode, Thomas Neumann, Ulf P Slabu, Ioana Roeth, Anjali A Int J Nanomedicine Original Research INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is a cancer with a meager prognosis due to its chemotherapy resistance. A new treatment method may be magnetic fluid hyperthermia (MFH). Magnetoliposomes (ML), consisting of superparamagnetic iron oxide nanoparticles (SPION) stabilized with a phospholipid-bilayer, are exposed to an alternating magnetic field (AMF) to generate heat. To optimize this therapy, we investigated the effects of MFH on human PDAC cell lines and 3D organoid cultures. MATERIAL AND METHODS: ML cytotoxicity was tested on Mia PaCa-2 and PANC-1 cells and on PDAC 3D organoid cultures, generated from resected tissue of patients. The MFH was achieved by AMF application with an amplitude of 40–47 kA/m and a frequency of 270 kHz. The MFH effect on the cell viability of the cell lines and the organoid cultures was investigated at two different time points. Clonogenic assays evaluated the impairment of colony formation. Altering ML set-ups addressed differences arising from intra- vs extracellular ML locations. RESULTS: Mia PaCa-2 and PANC-1 cells showed no cytotoxic effects at ML concentrations up to 300 µg(Fe)/mL and 225 µg(Fe)/mL, respectively. ML at a concentration of 225 µg(Fe)/mL were also non-toxic for PDAC organoid cultures. MFH treatment using exclusively extracellular ML presented the highest impact on cell viability. Clonogenic assays demonstrated remarkable impairment as long-term outcome in MFH-treated PDAC cell lines. Additionally, we successfully treated PDAC organoids with extracellular ML-derived MFH, resulting in notably reduced cell viabilities 2h and 24 h post treatment. Still, PDAC organoids seem to partly recover from MFH after 24 h as opposed to conventional 2D-cultures. CONCLUSION: Treatment with MFH strongly diminished pancreatic cancer cell viability in vitro, making it a promising treatment strategy. As organoids resemble the more advanced in vivo conditions better than conventional 2D cell lines, our organoid model holds great potential for further investigations. Dove 2021-04-23 /pmc/articles/PMC8079353/ /pubmed/33935496 http://dx.doi.org/10.2147/IJN.S288379 Text en © 2021 Palzer et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Palzer, Julian Mues, Benedikt Goerg, Richard Aberle, Merel Rensen, Sander S Olde Damink, Steven W M Vaes, Rianne D W Cramer, Thorsten Schmitz-Rode, Thomas Neumann, Ulf P Slabu, Ioana Roeth, Anjali A Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids |
title | Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids |
title_full | Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids |
title_fullStr | Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids |
title_full_unstemmed | Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids |
title_short | Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids |
title_sort | magnetic fluid hyperthermia as treatment option for pancreatic cancer cells and pancreatic cancer organoids |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079353/ https://www.ncbi.nlm.nih.gov/pubmed/33935496 http://dx.doi.org/10.2147/IJN.S288379 |
work_keys_str_mv | AT palzerjulian magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids AT muesbenedikt magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids AT goergrichard magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids AT aberlemerel magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids AT rensensanders magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids AT oldedaminkstevenwm magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids AT vaesriannedw magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids AT cramerthorsten magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids AT schmitzrodethomas magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids AT neumannulfp magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids AT slabuioana magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids AT roethanjalia magneticfluidhyperthermiaastreatmentoptionforpancreaticcancercellsandpancreaticcancerorganoids |